Reston, VA (March 6, 2026)—New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
Summaries of the newly published research articles are provided below.
PET/CT Scan Helps Uncover Causes of Fever of Unknown Origin
When patients develop persistent fevers without an obvious cause, doctors often struggle to identify why. In a large multicenter study of 929 patients, researchers examined how well an 18F-FDG PET/CT scan detects hidden infections, inflammatory diseases, or cancers and which clinical factors are linked to positive imaging results in patients.
First-in-Human Study Tests FAP-Targeted Radiotherapy for Advanced Solid Tumors
A first-in-human case series reports early clinical experience with the experimental radiopharmaceutical 177Lu-RTX-2358, which targets fibroblast activation protein (FAP) in advanced solid tumors. Six heavily pretreated patients received the therapy, with imaging used to track biodistribution, calculate radiation doses to organs and tumors, and evaluate preliminary treatment responses.
AI Tool Matches Expert Performance in Measuring Lymphoma Tumor Burden
Researchers tested an artificial intelligence model designed to automatically measure total metabolic tumor volume in lymphoma using 18F-FDG PET/CT scans. Trained on 1,500 cases, the system was evaluated against expert-segmented benchmark scans to assess how closely AI-derived tumor measurements matched those produced by nuclear medicine physicians.
PSMA Radioligand Therapy Shows Activity in Aggressive-Variant Prostate Cancer
Researchers evaluated outcomes of PSMA-targeted radioligand therapy in 82 patients with aggressive-variant prostate cancer, a high-risk form of metastatic disease typically treated with chemotherapy. The multicenter study compared prostate-specific antigen responses, progression-free survival, and overall survival between patients with aggressive-variant disease and those without.
Visit the JNM website for the latest research, and follow our new Twitter and Facebook
